RxDoctor Payments Data

Peter Moyer, DPM

Foot & Ankle Surgery · Rocky Mount, NCNPI 1811167125

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (29.9%), other and royalties or licence payments — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by In2bones USA, LLC at 31.1% of the total. 2025 is the largest year on record at $10,283, 5.8 times the $1,782 reported in 2019. Among foot & ankle surgery clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,990in general payments, 2019–2025

Across 154 payments — averaging $168.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • In2bones USA, LLC$8K
  • Convatec Inc.$6K
  • Linvatec Corporation$5K
  • Arthrex$3K
  • Polarityte, Inc.$1K
  • Misonix Inc$800
  • plus $3K from 37 others

What the payments were for

  • Royalty or licence$4,57118%
  • Consulting fees$7,76430%
  • Travel & lodging$2,1088%
  • Food & beverage$3,54714%
  • Education$2,4009%
  • Other$5,60022%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,990 in reported general payments places this provider in the 90th percentile of 196 foot & ankle surgery providers in North Carolina.

See all foot & ankle surgery providers in North Carolina

Medicare billing

Part B allowed, 2024
$728,499
Medicare patients
589
Services billed
44,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$4,874
Gentamicin Sulfate45$2,245
Linezolid11$1,715
Gabapentin165$1,433
Febuxostat15$969
Clorazepate Dipotassium25$882
Doxycycline Hyclate69$552
Colchicine16$489
Allopurinol87$438
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen50$433
CiclopiroxCiclopirox Olamine21$367
Terbinafine Hcl23$318
Pregabalin26$295
Mupirocin35$269
Silver Sulfadiazine29$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$99$4,87413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 196 foot & ankle surgery providers in North Carolina.

Other foot & ankle surgery in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →